Het beste van de ESC

0
240

#esccongress2013: Bijna dertigduizend afgevaardigden van over de hele wereld kwamen afgelopen week bijeen, om de ESC Congres 2013 in Amsterdam te bezoeken. Allemaal cardiologen die de laatste nieuwtjes eerste hand wilde horen geïnformeerd wilden worden over het laatste onderzoeksresultaten.

“Een record aantal Hot Lines en wetenschappelijke sessies met nieuwe formats passeerden de afgelopen dagen de revue. De kennisuitwisseling tussen collega’s presenteren de resultaten van klinisch onder onderzoek, nieuwe Clinical Practice Guidelines en nieuwe apparaten en behandelingen,”zo verelt Professor Keith Fox, voorzitter van de ESC Scientific Programme Committee. We hebben veel te leren van elkaar!

fox en Vardas op de fietsEnkele van de belangrijkste studies gepresenteerd op ESC Congress 2013, volgens Prof Fox waren:

 

  • HOKUSAI-VTE: The oral anticoagulant edoxaban for the treatment of venous thromboembolism (VTE) resulted in equal efficacy and better safety compared to standard warfarin, when either drug was used with initial low molecular weight heparin (LMWH)
  • TASTE: The aspiration of the blood clot or “thrombus” that causes a heart attack before re-opening a patient’s artery with a balloon catheter does not improve survival compared to performing balloon dilation and stenting alone
  • REALIGN: Results reaffirm current guidelines excluding patients with a narrow QRS for CRT, and expand the body of evidence that simple electrocardiographic determination of QRS duration remains the most important predictor of the clinical benefits of CRT, rather than measures of mechanical dyssynchrony by echocardiography. Based on the results of EchoCRT, the identification of patients who will obtain the benefit of CRT can be done most easily by a 12 lead-ECG.
  • DECAAF: Results showed that in patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not
  • PRAMI: Heart attack patients with ST elevation who undergo a preventive procedure to unblock additional coronary arteries have significantly better outcomes than those whose treatment is confined to the culprit blockage only.

“These studies will influence clinical practice and will allow us to better understand how to manage these important conditions and how to devise even newer therapies,” explained Prof Fox.

“We have come a long way in cardiovascular science, but many patients in Europe still do not have access to the latest treatments. This is unacceptable.” said Professor Panos Vardas, President of the ESC.

“Just as we have tackled innovation in the past – and we still do, as the enormous amount of research presented at this Congress shows – the society is now committed to making the needs of patients known to those in charge of designing and implementing policies in European institutions and in each of our member countries. We need to fight for better healthcare and guideline implementation.” he said.
Earlier this year the ESC and its sponsors published a White Paper on the state of research and development in cardiology calling for urgent investment in CVD innovation. With a growing ageing population and considering the increase of cardio metabolic diseases, doctors are expecting the incidence of CVD to rise in the future.

“We must not forget that CVD remains the number one killer in Europe.” said Prof Vardas.

“Studies such as PURE and EUROASPIRE IV confirm these differences and also the need to strive for better and equal access of patients in all countries to better prevention programmes, to the best treatment and also rehabilitation.” Prof Vardas concluded.

“Over five hundred journalists attended ESC Congress 2013,” said Kurt Huber, Chair of the ESC Press Committee. “Once again, they helped us reach out to the public with key prevention messages. Eighty per cent of CVD could be avoided if people adopted healthier lifestyles and there is a long way to go between knowing what should be done and doing.”

Some of the most popular “stories” with the wide range of media covering the event from Amsterdam were:

  • The Tour de France study demonstrating that French participants in the between 1947–2012 lived longer than their same-age French counterparts
  • Listening to music that makes you happy and relaxed alone and in addition to regular exercise training improves endothelial function (by releasing endorphins)
  • Cold weather is by far the most important environmental trigger for heart attacks whereas air pollution has a lesser effect
  • Statins show protective effect preventing cataracts, the leading cause of visual impairment worldwide affecting more than 20 million people

Prof Fox concluded: “It was great to see hundreds of doctors cycling to the congress centre in the morning. Let’s just hope that their example will help drive home the importance of exercise to live a long and healthy life, even if we cannot emulate our Tour de France heroes!”

Vorig artikel‘A match made in Heaven’ op 3 september in Haarlem levert investeerders op
Volgend artikelGaming kan mentale aftakeling vertragen
Ik heb mij gespecialiseerd in interactief nieuws voor zorgverleners, zodat zorgverleners elke dag weer op de hoogte zijn van het nieuws wat voor hen relevant kan zijn. Zowel lekennieuws als nieuws specifiek voor zorgverleners en voorschrijvers. Social Media, Womens Health, Patient advocacy, patient empowerment, personalized medicine & Zorg2.0 zijn voor mij speerpunten om extra aandacht aan te besteden. Ik studeerde Fysiotherapie en Health Care bedrijfskunde. Ik heb veel ervaring in diverse functies in de medische- , farmaceutische industrie en de gezondheidszorg. En heb brede medische kennis van de meeste specialismen in de zorg. Ik ga jaarlijk naar de meeste toonaangevende medisch congressen in Europa en Amerika om mijn kennis up-to-date te houden en bij te blijven op de laatste ontwikkelingen en innovaties De berichten van mij op deze weblog vormen geen afspiegeling van strategie, beleid of richting van een werkgever noch zijn het werkzaamheden van of voor een opdrachtgever of werkgever.